


Phenoxodiol

Cat. No.:	HY-13721		
CAS No.:	81267-65-4		
Molecular Formula:	C ₁₅ H ₁₂ O ₃		
Molecular Weight:	240		
Target:	Caspase; Apoptosis; Topoisomerase		
Pathway:	Apoptosis; Cell Cycle/DNA Damage		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (416.67 mM)
 H₂O : < 0.1 mg/mL (insoluble)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	4.1667 mL	20.8333 mL	41.6667 mL
	5 mM	0.8333 mL	4.1667 mL	8.3333 mL
	10 mM	0.4167 mL	2.0833 mL	4.1667 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.5 mg/mL (10.42 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: ≥ 2.5 mg/mL (10.42 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2.5 mg/mL (10.42 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Phenoxodiol (Idronoxil), a synthetic analog of Genestein, activates the mitochondrial caspase system, inhibits XIAP (an apoptosis inhibitor), and sensitizes the cancer cells to Fas-mediated apoptosis. Phenoxodiol also inhibits DNA topoisomerase II by stabilizing the cleavable complex. Phenoxodiol induces cell cycle arrest in the G1/S phase of the cell cycle and upregulates p21^{WAF1} via a p53 independent manner^{[1][2]}.

IC ₅₀ & Target	Caspase, DNA topoisomerase II ^{[1][2]} .	
In Vitro	<p>Phenoxodiol (Idronoxil) (0-10 µg/mL; 24 h) decreases cell viability of primary ovarian cancer cells^[1].</p> <p>Phenoxodiol (0-10 µg/mL; 24 h) induces apoptosis and restores sensitivity to Fas-mediated apoptosis in ovarian cancer cells^[1].</p> <p>Phenoxodiol (0-10 µg/mL; 24 h) induces caspase-8 activation and FLIP downregulation through the Akt-pathway.</p> <p>Phenoxodiol-induced apoptosis involves activation of the mitochondrial pathway and is caspase dependent. Phenoxodiol treatment results in downregulation and cleavage of XIAP^[1].</p> <p>Phenoxodiol (10 and 30 µM; 24 and 48 h) induces cell cycle arrest in the G1/S phase of the cell cycle in prostate cancer cells^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p>	
	Cell Line:	R182s, R127, Hey, CP70, A2780, R187, R188, R207 and OSE cells
	Concentration:	0, 0.01, 0.1, 1 and 10 µg/mL
	Incubation Time:	24 h
	Result:	A significant decrease in cell viability in all the ovarian cancer cell cultures was observed at a concentration of 10 µg/mL (41.6 µM) and did not affect ovarian surface epithelial (OSE) cells' viability. In CP70 cells, the IC ₅₀ was 1.35 µM.
	Apoptosis Analysis ^[1]	
	Cell Line:	CP70 and OSE cells
	Concentration:	10 µg/mL
	Incubation Time:	24 h
	Result:	Induced apoptosis and resulted in a twofold increase in caspase-3 activity. No change in caspase-3 activity was found in normal OSE cells.
	Western Blot Analysis ^[1]	
	Cell Line:	Ovarian cancer cells
Concentration:	10 µg/mL	
Incubation Time:	24 h	
Result:	Induced caspase-8 activation, characterized by cleavage of procaspase-8 into its p43/41 and p28 forms and in downregulation of the p43 form of FLIP in all the primary cultures as well as in the CP70 and Hey cell lines. Decreased the levels of Akt expression. Resulted in XIAP downregulation and cleavage to its 30 kDa inactive form.	
Cell Cycle Analysis ^[2]		
Cell Line:	LNCaP, DU145 and PC3 cells	
Concentration:	10 and 30 µM	
Incubation Time:	24 and 48 h	
Result:	Induced significantly decreased G2 phase cell populations versus DMSO vehicle control, over 24 hours for both 10 µM and 30 µM treatments. The S phase cell population was found to increase versus DMSO vehicle control.	

RT-PCR^[2]

Cell Line:	LNCaP, DU145 and PC3 cells
Concentration:	10 and 30 μ M
Incubation Time:	24 and 48 h
Result:	PC3 cells were found to significantly increase the expression of c-Myc at 30 μ M after 48 h. Decreased the expression of Cyclin-D1 after 24 hours of treatment with 30 μ M in DU145 and PC3 cells. Decreased the expression of Ki-67 after 24 hours of treatment with 10 and 30 μ M in LNCaP and PC3 cells. Increased the expression of p21 in LNCaP and PC3 cells.

REFERENCES

- [1]. Kamsteeg M, et al. Phenoxodiol--an isoflavone analog--induces apoptosis in chemoresistant ovarian cancer cells. *Oncogene*. 2003 May 1;22(17):2611-20.
- [2]. Mahoney S, et al. The effects of phenoxodiol on the cell cycle of prostate cancer cell lines. *Cancer Cell Int*. 2014 Nov 8;14(1):110.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA